First author [ref.] | Sample size n | Mean follow-up time months | PH assessment method | Mean sPAP after closure mmHg | Mean sPAP reduction mmHg | PH prevalence | NYHA class III–IV |
Veldtman [31] | 27 | NR (1–12) | TTE | NR | 10# | 28.5 | 0 |
De Lezo [32] | 28 | 21±14 | TTE | 34±11 | 14# | 100 | 0 |
Bruch [33] | 13 | 10±4 | RHC | 49.9±17.8 | NR | 92 | 0 |
Balint [34]¶ | 39 | 31±15 | TTE/TEE | 44±16 | 14# | NR | 20 |
Yong [35]¶ | 186 | Median (IQR) 15 (8–43) | TTE | Median (IQR) 25.0 (24–49) | Median (IQR) 5 (1–13) | 26 | 3.7 |
Yalonetsky [60] | NR | NR (1–12) | TTE | NR | NR | NR | |
Age 40–60 years | 26 | ||||||
Age >60 years | 33.5 | ||||||
Altindag [37] | 41 | 15±15 | TTE/TEE | NR | NR | 38 | 5 |
Humenberger [38]¶ | 28±19 | TTE | NR | ||||
Age <40 years | 75 | 26±5 | 5±8 | 0 | |||
Age 40–60 years | 84 | 30±6 | 8±9 | 0 | |||
Age >60 years | 74 | 43±14 | 9±14 | 4 | |||
Huang [39]¶,+ | 7 | 23.4±9.7 | RHC/TTE | 21.0±3.8 | 16# | 13 | NR |
Kefer [40] | 112 | 60±34 | TTE | 31±11 | 7# | 5.4 | 8 |
Nakagawa [41]¶ | 27 | 19.1±11.3 | TEE | 27.2±7.3 | NR | NR | 4 |
Mangiafico [42] | NR (1–12) | TTE | NR | ||||
Age <40 years | 10 | 28±2.8 | 7.1# | 0 | |||
Age >40 years | 20 | 28.4±6.5 | 12.8# | 0 | |||
Akagi [9]¶ | TTE | NR | NR | ||||
PHM group 1 | 8 | 19±27 (3–83) | 40±9 | 0 | |||
non-PHM group 2 | 14 | 19±16 (4–61) | 38±10 | 0 | |||
Wang [43] | 176 | 45.6±25.2 | TEE | NR | NR | 7 | 1.7 |
Dalvi [44] | 4 | 39.5±8.5 | RHC | 55.7±9.2 | 12.8# | NR | 0 |
Data are presented as mean±sd, mean (range) or %, unless otherwise stated. PH: pulmonary hypertension; sPAP: systolic pulmonary artery pressure; NYHA: New York Heart Association; PHM: pulmonary hypertension medication; NR: not reported; TTE: transthoracic echocardiography; RHC: right heart catheterisation; TEE: transoesophageal echocardiography. #: when mean sPAP reductions were not reported, we calculated (mean sPAP before closure (mmHg)) – (mean sPAP after closure (mmHg)); ¶: study reported values for pulmonary arterial hypertension; +: study reported mean values as mPAP.